Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

• Published in: Cancer research (Chicago, Ill.) Vol. 45; no. 6; pp. 2859 - 2865
• Main Authors: MELINK, T. J, VON HOFF, D. D, KUHN, J. G, HERSH, M. R, STEMSON, L. A, PATTON, T. F, SIEGLER, R, BOLDT, D. H, CLARK, G. M
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.1985
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Agents - adverse effects; Antineoplastic Agents - metabolism; Aspartate Aminotransferases - blood; Biological and medical sciences; Bone Marrow - drug effects; Chemotherapy; Creatine Kinase - blood; Drug Evaluation; Female; Humans; Kinetics; Lymphocytes - drug effects; Male; Medical sciences; Middle Aged; Neoplasms - drug therapy; Pharmacology. Drug treatments; Ribavirin - adverse effects; Ribavirin - analogs & derivatives; Ribavirin - metabolism; Ribonucleosides - adverse effects; Uric Acid - blood; Antineoplastic agent; Human; C-Nucleoside; Chemotherapy; Toxicity; Phase I trial; Tumor; Pharmacokinetics
• ISSN: 0008-5472; 1538-7445

Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor activity against several murine tumor models, including Lewis lung carcinoma. The mechanism whereby this compound exerts its antineoplastic effects is most likely related to a state of guanine nucleotide depletion whereby the anabolite, thiazole-4-carboxamide adenine dinucleotide, potently inhibits inosine-5'-monophosphate dehydrogenase. This Phase I study was designed to determine the maximally tolerated dose of Tiazofurin administered on a 5-day, every-28-day schedule. Tiazofurin levels were measured using a high-pressure liquid chromatography assay, and pharmacokinetic studies were performed in patients treated at each dose level. Nineteen patients received a total of 24 courses of the drug in doses ranging from 550 to 2200 mg/sq m. The dose-limiting toxicities were pleuropericarditis and a general illness best described as a "viral-like" syndrome (manifested by severe malaise, headaches, myalgias, fever, nausea, vomiting, and diarrhea). Other toxicity included myelosuppression, hyperuricemia, elevated serum creatine phosphokinase and serum glutamic oxaloacetic transaminase, conjunctivitis, mucositis, and desquamation of the palms of the hands. Plasma clearance of Tiazofurin followed a biexponential pattern with a harmonic mean terminal half-life of 7.6 h. The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m. The total cumulative urinary excretion ranged from 15 to 49%. The maximally tolerated dose of Tiazofurin on a 5-day schedule was 1650 mg/sq m. The recommended dose for Phase II evaluations is 1100 mg/sq m for 5 days. However, exploration of other schedules which might allow administration of more Tiazofurin combined with biochemical studies including thiazole-4-carboxamide adenine dinucleotide measurements would be desirable.